Eiger BioPharmaceuticals, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following press release that they conduct preclinical trials on animals.
“LTB4 is a naturally-occurring inflammatory mediator known to be elevated in both animal models of PAH as well as human PAH disease.” Read the full document.
Eiger BioPharmaceuticals, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of biopharmaceutical products. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA. [Source: MarketWatch]
Company Website: http://www.eigerbio.com